Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
about
Long-chain acyl-CoA synthetase 4 modulates prostaglandin E₂ release from human arterial smooth muscle cellsPlatelet signaling: a complex interplay between inhibitory and activatory networksCigarette Smoke Amplifies Inflammatory Response and Atherosclerosis Progression Through Activation of the H1R-TLR2/4-COX2 AxisThe contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failurePathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activationElucidation of monocyte/macrophage dynamics and function by intravital imaging.Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axisHuman thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysisDetection of high-risk atherosclerotic plaques with ultrasound molecular imaging of glycoprotein IIb/IIIa receptor on activated platelets.Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production.Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosisAnti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice.Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.Hyperglycemia via activation of thromboxane A2 receptor impairs the integrity and function of blood-brain barrier in microvascular endothelial cells.Enhanced tyrosine nitration of prostacyclin synthase is associated with increased inflammation in atherosclerotic carotid arteries from type 2 diabetic patients.Chronic ingestion of H1-antihistamines increase progression of atherosclerosis in apolipoprotein E-/- mice.Thromboxane and the thromboxane receptor in cardiovascular disease.Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers.Prostaglandins and inflammation.PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease.The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake.Hypercholesterolemia and microvascular dysfunction: interventional strategies.Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis.Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation.Internalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6.Adventures in vascular biology: a tale of two mediators.Clinical pharmacology of etoricoxib.Prostacyclin: an inflammatory paradox.Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.PGE(2) -EP(2) signalling in endothelium is activated by haemodynamic stress and induces cerebral aneurysm through an amplifying loop via NF-κB.Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation.Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyEndothelium-mediated control of vascular tone: COX-1 and COX-2 products.
P2860
Q24337408-4196CDD5-921B-4024-9C96-56F0CB7C06B4Q26765384-C29121BF-2C7A-4497-A269-445304C67CDEQ26776119-CBE837D9-F251-455F-9781-3F76F7ACE5E0Q26830372-9CCB59D9-AEA7-41AE-9001-6D013FC98C7BQ26864770-B53FCBEC-24A2-4820-AFC0-551B1C7DEDDCQ27313900-9554977D-1075-4B48-9605-0BD489D3F48FQ28210322-BD77E438-2C82-42D2-953F-580B397FC540Q28274624-646E388E-86B1-4910-9554-F17E32AB614CQ28510556-D7D11067-21D5-496C-AB53-8CE99FAAD7C1Q28534432-1C97E453-4427-4891-9761-2ACC394B6D3BQ30408017-2ABAF73D-D15A-49FD-B3D2-3705722064DFQ30423459-8345B51B-B54D-4605-A336-DC22378B7554Q30494712-DCCDB406-B6AE-47C8-BC7C-65EB56522B15Q33477092-E48BBA7E-12F2-46CD-9FF0-7AA9F956DC29Q33607097-4C4EE0F1-FE6E-48F4-992B-81F1DD932AE5Q33728222-2C391A17-0764-463F-AAED-EEFFFE3F03CCQ33816483-8DF4F7F1-F87F-4CD6-AB29-A9A1466C0D79Q33895956-D46546BD-C93F-49EA-B3E5-66E4EBC15810Q33899567-1FD1696A-F4BB-45E9-87F4-CE8E11A340A8Q33937192-C558E3D0-8BF8-43A6-AB49-FCA22023EC47Q34019117-FB7F45C7-9D36-4C7B-ADB6-F7CEF683C330Q34021188-B8742DD7-7887-40EE-9800-D7701B4DACFFQ34179727-9BD3D7F5-FFF0-4E3B-AFD8-11554A2299A8Q34186949-0B721CC4-62D9-4048-AB85-5539FEDBE81EQ34228685-A223F254-1A13-4A5B-A70F-95E6B4BB477EQ34245387-3E4A1843-3584-4A4A-A514-11C7C046DF12Q34361591-A45D7000-8D8B-43AD-BF11-7BAA99C0FA69Q34375542-DF02B47D-962E-43D8-9152-7CA21C3D333CQ34389439-A9C2F133-E01C-4533-A78A-5CC1AC3A7989Q34415503-EB65ACAF-C68F-4A5B-B20E-C0E27B75211CQ34435166-C39371C5-A941-4716-8F94-561180CE805FQ34500980-3007D389-A265-42EA-AD49-7CEC84C3B219Q34515584-183E2BA2-E30C-4458-885B-8CC1019B97CCQ34570225-11378989-DDA1-4ACA-B3EB-1E6C4DC9F99FQ35025863-43ABC578-99E7-4733-A3CA-631857A82DDFQ35029268-B60E89EC-3125-4E21-9314-C2323539D1F9Q35130538-4B4B6CD3-B0D0-4EDC-9C02-994B6A2F1CDDQ35367168-4BD52D0E-B6C2-4BCF-8AC2-11DAFA3474C4Q35373624-D19CDB02-29F0-4898-AB95-858FDF4D0E9BQ35376020-E7DFBDFB-D26A-4030-9F63-9102A1B219D7
P2860
Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Roles of thromboxane A
@nl
Roles of thromboxane A(2) and ...... erosis in apoE-deficient mice.
@en
type
label
Roles of thromboxane A
@nl
Roles of thromboxane A(2) and ...... erosis in apoE-deficient mice.
@en
prefLabel
Roles of thromboxane A
@nl
Roles of thromboxane A(2) and ...... erosis in apoE-deficient mice.
@en
P2093
P2860
P356
P1476
Roles of thromboxane A(2) and ...... erosis in apoE-deficient mice.
@en
P2093
Hidenori Arai
Hideto Sano
Hiroji Oida
Hiroyuki Katagiri
Jun K Yamashita
Masako Iguchi
Masataka Majima
Masayuki Yokode
Mayumi Matsumoto
Shuh Narumiya
P2860
P304
P356
10.1172/JCI200421446
P407
P577
2004-09-01T00:00:00Z